Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Xilio Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- 0 vs. Q4 2024
- Shares held
- 22.5M
- −3.33M (−12.9%) vs. Q4 2024
- Total value
- $16.3M
- −$8.37M (−33.9%) vs. Q4 2024
- New holders
- 6
- 8 more added
- Sold out
- 6
- 7 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 9,105,451 | $6.60M | 0.56% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 4,566,817 | $3.31M | 0.49% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,483,758 | $1.07M | 0.65% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.07M | 6.59% | 00.0% | Unchanged |
| Morgan Stanley | 1,155,838 | $837.3K | 0.00% | +154,479+15.4% | Added |
| Vanguard Group Inc | 1,135,716 | $822.3K | 0.00% | +233,185+25.8% | Added |
| FMR LLC | 884,035 | $640.4K | 0.00% | −511,818−36.7% | Reduced |
| AJU IB Investment Co., Ltd. | 667,742 | $483.7K | 0.58% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 379,016 | $274.6K | 0.00% | +20,594+5.7% | Added |
| Balyasny Asset Management LLC | 254,346 | $184.2K | 0.00% | −88,884−25.9% | Reduced |
| Trustees of Columbia University in the City of New York | 249,635 | $180.7K | 0.03% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 177,700 | $128.7K | 0.00% | −118,917−40.1% | Reduced |
| UBS Group AG | 163,101 | $118.1K | 0.00% | −86,300−34.6% | Reduced |
| Avantax Planning Partners, Inc. | 150,399 | $108.9K | 0.00% | +150,399 | New |
| Two Sigma Investments, LP | 84,068 | $60.9K | 0.00% | +73,244+676.7% | Added |
| BlackRock, Inc. | 74,700 | $54.1K | 0.00% | −1,386−1.8% | Reduced |
| Bridgeway Capital Management, LLC | 71,081 | $51.5K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 66,609 | $48.3K | 0.00% | +27,401+69.9% | Added |
| Millennium Management LLC | 51,110 | $37.0K | 0.00% | +51,110 | New |
| SevenBridge Financial Group, LLC | 46,000 | $33.6K | 0.01% | +5,000+12.2% | Added |
| Aptus Capital Advisors, LLC | 46,000 | $33.3K | 0.00% | +5,000+12.2% | Added |
| State Street Corp | 43,390 | $31.4K | 0.00% | 00.0% | Unchanged |
| Scientech Research LLC | 42,546 | $30.8K | 0.01% | +42,546 | New |
| ADAR1 Capital Management, LLC | 40,000 | $29.0K | 0.01% | +40,000 | New |
| Raymond James Financial Inc | 33,961 | $24.6K | 0.00% | −16,125−32.2% | Reduced |
| Mariner, LLC | 25,000 | $18.1K | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 20,000 | $14.5K | 0.00% | 00.0% | Unchanged |
| Dunhill Financial, LLC | 10,274 | $7.44K | 0.00% | +10,274 | New |
| Pinnacle Financial Group, LLC | 10,000 | $7.24K | 0.00% | 00.0% | Unchanged |
| Investors Asset Management of Georgia Inc | 10,000 | $7.24K | 0.00% | +10,000 | New |
| Federation des caisses Desjardins du Quebec | 3,300 | $2.39K | 0.00% | 00.0% | Unchanged |
| Key Financial Inc | 830 | $601 | 0.00% | 00.0% | Unchanged |
| Private Wealth Management Group, LLC | 310 | $225 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 290 | $210 | 0.00% | +25+9.4% | Added |
| JPMorgan Chase & Co | 62 | $45 | 0.00% | −4−6.1% | Reduced |
| Rock Springs Capital Management LP | 0 | $0 | 0.00% | −3,003,259−100.0% | Sold out |
| FIL Ltd | 0 | $0 | 0.00% | −218,705−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −49,093−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −40,316−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −12,870−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −2,729−100.0% | Sold out |